Sepsis News and Research

Latest Sepsis News and Research

Research Roundups: Expanding Medicaid; More spending doesn't reduce mortality; Colonoscopy cost effectiveness; Kids, asthma and access to care

Health Affairs: Little Evidence Of Correlation Between Growth In Health Care Spending And Reduced Mortality - This study examines differences in hospital mortality and cost between 2000 and 2004 for patients at 122 U.S. hospitals, with seven common medical diagnoses: acute myocardial infarction, chronic obstructive pulmonary disease, community-acquired pneumonia, congestive heart failure, cerebrovascular accident (also called ischemic stroke), sepsis, or urinary tract infection.

7 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Blood coagulation, antimicrobial defence processes are functionally coupled: Research

The adaptive immune system can recognize and respond specifically to particular infectious agents. But the first line of defence against pathogens is the so-called innate immune system. This system reacts to invaders by initiating unspecific inflammatory responses which attract various types of specialized cells such as neutrophils to the site of the incursion.

4 Aug 2010

Targacept licenses Cornerstone technology for inflammatory disorders program

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has added to its program for inflammatory disorders by entering into an exclusive worldwide license agreement with Cornerstone Therapeutics Inc. The agreement grants Targacept rights to Cornerstone's NNR-based patents, as well as its library of preclinical compounds that act on the alpha7 or other nicotinic receptors.

4 Aug 2010

Study analyzes prevalence of pediatric patient-safety events at hospitals

Hospital-acquired infections are the leading cause of potentially preventable mortality among pediatric patients, according to a study of pediatric patient-safety incidents issued today by HealthGrades, the leading independent health care ratings organization.

4 Aug 2010

Research findings could lead to new drugs that reduce severity of blood infections leading to sepsis

Scientists have made an important discovery that could lead to new drugs that reduce the severity of blood infections leading to sepsis. Research presented in the August 2010 issue of Journal of Leukocyte Biology shows how interfering with the function of the cell membrane protein called "Programmed Death 1" (PD-1) improves survival in a clinically relevant model of severe infection.

2 Aug 2010

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.

28 Jul 2010

Allos reports net loss of $20.0 million for second-quarter 2010

Allos Therapeutics, Inc. today reported its financial results and business highlights for the quarter and six months ended June 30, 2010.

28 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Schizophrenia patients likely to sustain medical injuries during non-psychiatric hospital stay

People with schizophrenia are more likely than others to sustain medical injuries during non-psychiatric hospital stays, a large national study finds.These findings confirm that medical and surgical hospitalizations are an at-risk time for this group, and a national problem, said lead study author Elizabeth Khaykin, at the Department of Mental Health at Bloomberg Johns Hopkins School of Public Health.

23 Jul 2010

Study finds sepsis 10 times more common and lethal than heart attacks, blood clots

New research from The Methodist Hospital in Houston shows that sepsis is 10 times more common and more lethal than other more well-known surgical complications including heart attacks and blood clots. These results, published today in the Archives of General Surgery, show a greater need for sepsis awareness and early recognition during and after surgery.

21 Jul 2010

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AiCuris announced today publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246 is a novel anti-HCMV drug currently in clinical phase 2 testing.

21 Jul 2010

Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research

A pneumococcal conjugate vaccine introduced in the U.S. 10 years ago appears to reduce pneumonia and serious associated complications, such as blood infections, in the vaccine's target range, children less than a year old, according to new research.

19 Jul 2010

MD Buyline identifies top emerging technologies with highest impact

This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.

15 Jul 2010

Biggest breasted woman seriously ill after breast augmentation surgery

Brazilian model Sheyla Hershey, 30 apparently with the largest breasts in the world is seriously ill with complications following her latest breast augmentation surgery. Ms Hershey who lives in Houston, Texas contracted a severe staphylococcal infection after her surgery in June.

13 Jul 2010

Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards announced

URAC announced today that a distinguished panel of judges has selected 30 finalists for its Best Practices in Health Care Consumer Empowerment and Protection Awards. The competition drew entries from across the nation. The finalists will be honored during URAC's 11th Annual Quality Summit, October 5-7, 2010 in Chicago, IL. The awards honor programs in two areas: Consumer Decision-Making and Consumer Health Improvement.

13 Jul 2010

Efficacy data of Caldolor Injection in treating fever associated with falciparum malaria published

Cumberland Pharmaceuticals Inc. today announced that data supporting the efficacy of Caldolor in treating fever associated with falciparum malaria was published in the July edition of the peer-reviewed American Journal of Tropical Medicine and Hygiene. The study, which is the first to document an antipyretic effect of an injectable non-steroidal anti-inflammatory drug on fever caused by malaria, demonstrated that patients who received intravenous ibuprofen experienced a greater reduction in their temperatures than those who received placebo.

13 Jul 2010

European Commission approves new indication for ORENCIA in combination with MTX for RA

Bristol-Myers Squibb Company has today announced that on 1 July 2010 the European Commission approved a new indication for ORENCIA® (abatacept), in combination with methotrexate (MTX), for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including MTX or a TNF-alpha inhibitor.

7 Jul 2010

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 (HMGB1) related technology from MedImmune, LLC.

6 Jul 2010

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

United Therapeutics Corporation and Lee's Pharmaceutical Holdings Ltd. announced today that they have entered into an exclusive agreement for the distribution of Remodulin (treprostinil) Injection in China. Remodulin is a subcutaneously or intravenously administered prostacyclin analogue for the treatment of pulmonary arterial hypertension. Lee's Pharmaceutical is a leading Chinese pharmaceutical company with both a strong cardiovascular focus and extensive commercialization experience.

2 Jul 2010

Sepsis News and Research

Latest Sepsis News and Research

Research Roundups: Expanding Medicaid; More spending doesn't reduce mortality; Colonoscopy cost effectiveness; Kids, asthma and access to care

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Blood coagulation, antimicrobial defence processes are functionally coupled: Research

Targacept licenses Cornerstone technology for inflammatory disorders program

Study analyzes prevalence of pediatric patient-safety events at hospitals

Research findings could lead to new drugs that reduce severity of blood infections leading to sepsis

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports net loss of $20.0 million for second-quarter 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Schizophrenia patients likely to sustain medical injuries during non-psychiatric hospital stay

Study finds sepsis 10 times more common and lethal than heart attacks, blood clots

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research

MD Buyline identifies top emerging technologies with highest impact

Biggest breasted woman seriously ill after breast augmentation surgery

Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards announced

Efficacy data of Caldolor Injection in treating fever associated with falciparum malaria published

European Commission approves new indication for ORENCIA in combination with MTX for RA

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Sepsis News and Research

Latest Sepsis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in